ARENA PHARMACEUTICALS INC's ticker is ARNA and the CUSIP is 040047607. A total of 237 filers reported holding ARENA PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 0.58 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $40,510,000 | +38.3% | 435,870 | -11.4% | 0.03% | +33.3% |
| Q3 2021 | $29,287,000 | -13.6% | 491,800 | -1.0% | 0.02% | -8.7% |
| Q2 2021 | $33,882,000 | -3.1% | 496,800 | -1.4% | 0.02% | -4.2% |
| Q1 2021 | $34,979,000 | -11.0% | 504,090 | -1.4% | 0.02% | -17.2% |
| Q4 2020 | $39,299,000 | -1.0% | 511,500 | -3.6% | 0.03% | -12.1% |
| Q3 2020 | $39,691,000 | +13.7% | 530,700 | -4.3% | 0.03% | +10.0% |
| Q2 2020 | $34,910,000 | +43.3% | 554,570 | -4.4% | 0.03% | +25.0% |
| Q1 2020 | $24,360,000 | -58.5% | 580,000 | -55.1% | 0.02% | -44.2% |
| Q4 2019 | $58,637,000 | -6.2% | 1,291,000 | -5.5% | 0.04% | -14.0% |
| Q3 2019 | $62,522,000 | -30.1% | 1,366,000 | -10.4% | 0.05% | -24.2% |
| Q2 2019 | $89,422,000 | +36.4% | 1,525,200 | +4.3% | 0.07% | +37.5% |
| Q1 2019 | $65,550,000 | +15.0% | 1,462,200 | -0.1% | 0.05% | +4.3% |
| Q4 2018 | $57,023,000 | +25.4% | 1,464,000 | +48.1% | 0.05% | +48.4% |
| Q3 2018 | $45,486,000 | – | 988,399 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 163,133 | $7,467,000 | 4.14% |
| PFM Health Sciences, LP | 2,271,536 | $103,968,000 | 3.07% |
| Partner Investment Management, L.P. | 28,877 | $1,322,000 | 2.26% |
| Atika Capital Management LLC | 181,000 | $8,284,000 | 1.74% |
| DAFNA Capital Management LLC | 93,942 | $4,300,000 | 1.62% |
| Asymmetry Capital Management, L.P. | 16,272 | $745,000 | 1.60% |
| First Light Asset Management, LLC | 190,838 | $8,735,000 | 1.32% |
| Perceptive Advisors | 953,129 | $43,624,000 | 1.18% |
| Rhenman & Partners Asset Management AB | 155,000 | $7,094,000 | 0.89% |
| Opus Point Partners Management, LLC | 9,770 | $447,000 | 0.81% |